Evaluation of tamsulosin and alfuzosin activity in the rat vas deferens: Relevance to ejaculation delays

Journal of Pharmacology and Experimental Therapeutics

Volumn 312, Issue 2, 2005, Pages 710-717

  Tambaro, Simone ^a   Ruiu, Stefania ^a   Dessi, Christian ^a   Mongeau, Raymond ^a   Marchese, Giorgio ^a   Pani, Luca ^a,b  

^a Neuroscienze PharmaNess Scarl   (Italy)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; NORADRENALIN; TAMSULOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; EJACULATION; EJACULATION DISORDER; ELECTROPHYSIOLOGY; EPIDIDYMIS; IN VITRO STUDY; MALE; MUSCLE ISOMETRIC CONTRACTION; MUSCLE TWITCH; NERVE STIMULATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; RAT; SPIKE WAVE; VAS DEFERENS;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; EJACULATION; ELECTRIC STIMULATION; EPIDIDYMIS; MALE; MUSCLE CONTRACTION; NOREPINEPHRINE; QUINAZOLINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; VAS DEFERENS; VASOCONSTRICTOR AGENTS;

EID: 13244283099     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.104.074740     Document Type: Article

References (34)

1. Aboud R, Shafii M, and Docherty JR (1993) Investigation of the subtypes of alpha 1-adrenoreceptor mediating contractions of rat aorta, vas deferens and spleen. Br J Pharmacol 109:80-87.
2. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
3. Boselli C, Bianchi L, Barbieri A, and Grana E (1998) Effect of calcium antagonists on the response to NA in the whole and bisected rat vas deferens. J Auton Pharmacol 18:297-306.
4. Brown DA, Docherty JR, French AM, MacDonald A, McGrath JC, and Scott NC (1983) Separation of adrenergic and non-adrenergic contractions to field stimulation in rat vas deferens. Br J Pharmacol 79:379-393.
5. Burt RP, Chapple CR, and Marshall I (1995) Evidence for a functional alpha 1A-(alpha 1C-) adrenoceptor mediating contraction of the rat epididymal vas deferens and an alpha 1B-adrenoceptor mediating contraction of the rat spleen. Br J Pharmacol 115:467-475.
6. 2+ influx stimulated by diacylglycerol and PKC. Br J Pharmacol 123:317-325.
7. Caine M, Pfau A, and Perleberg S (1976) The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol 48:255-263.
8. Carbone DJ Jr and Hodges S (2003) Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 15:299-306.
9. 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol 288:201-207.
10. 1c subtype. Mol Pharmacol 45:703-708.
11. Giuliano F, Bernabe J, Droupy S, Alexandre L, and Allard J (2004) A comparison of the effects of tamsulosin and alfuzosin on neurally evoked increases in bladder neck and seminal vesicle pressure in rat. BJU Int 93:605-608.
12. 2+ in smooth muscle. Nature (Lond) 329:333-335.
13. Hanft G and Gross G (1989) Subclassification of alpha 1-adrenoceptor recognition sites by urapidil derivatives and other selective antagonists. Br J Pharmacol 97:691-700.
14. 1-adrenoceptors: consensus update. Pharmacol Rev 47:267-270.
15. 1-adrenoceptor mediating contractions of rat vas deferens. Br J Pharmacol 128:1323-1331.
16. 1 adrenoceptors: binding, functional and in vivo studies. Br J Pharmacol 118:871-878.
17. 1-adrenoceptor antagonist in the lower urinary tract. Br J Pharmacol 109:1282-1289.
18. Leonardi A, Hieble JP, Guarneri L, Naselsky DP, Poggesi E, Sironi G, Sulpizio AC, and Testa R (1997) Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. J Pharmacol Exp Ther 281:1272-1283.
19. Lepor H (1993) Medical therapy for benign prostatic hyperplasia. Urology 42:483-501.
20. Lepor H (1998) Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 51:892-900.
21. Lepor H, Tang R, Kobayashi S, Shapiro E, Forray C, Wetzel JM, and Gluchowski C (1995) Localization of the alpha 1A-adrenoceptor in the human prostate. J Urol 154:2096-2099.
22. 2+ channel-mediated responses in rat vas deferens. Gen Pharmacol 27:689-693.
23. McKeage K and Plosker GL (2002) Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 62:633-653.
24. 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol 16:21-28.
25. 1-adrenoceptor subtypes. Naunyn- Schmiedeberg's Arch Pharmacol 350:136-142.
26. 1-adrenoceptor subtypes. Naunyn-Schmiedeberg's Arch Pharmacol 352:1-10.
27. Monda JM and Oesterling JE (1993) Medical treatment of benign prostatic hyperplasia: 5 alpha-reductase inhibitors and alpha-adrenergic antagonists. Mayo Clin Proc 68:670-679.
28. Moritoki H, Iwamoto T, Kanaya J, Maeshiba Y, Ishida Y, and Fukuda H (1987) Verapamil enhances the non-adrenergic twitch response of rat vas deferens. Eur J Pharmacol 140:75-83.
29. 1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol 123:1289-1293.
30. 1D- adrenoceptor subtypes. Br J Pharmacol 120:231-238.
31. Price DT, Schwinn DA, Lomasney JW, Allen LF, Caron MG, and Lefkowitz RJ (1993) Identification, quantification and localization of mRNA for three distinct alpha-1-adrenergic receptor subtypes in human prostate. J Urol 150:546-551.
32. 1-adrenergic receptor subtypes. Prostate 33:55-59.
33. Sneddon P and Machaly M (1992) Regional variation in purinergic and adrenergic responses in isolated vas deferens of rat, rabbit and guinea-pig. J Auton Pharmacol 12:421-428.
34. Vizi ES and Sperlágh B (1999) Receptor- and carrier-mediated release of ATP of postsynaptic origin: cascade transmission. Prog Brain Res 120:159-169.